Scholarlink

Background <p>Ribonuclease P/MRP subunit p40 (<i>RPP40</i>) is a core component of the RNase P/MRP ribonucleoprotein complex, playing a central role in RNA processing. However, its systematic characteristics, clinical significance, and functional mechanisms at the pan-cancer level remain unclear.</p> Methods <p>We systematically characterized the pan-cancer expression profile and prognostic value of <i>RPP40</i> using multi-omics approaches, including pan-cancer expression profiling, CRISPR screening, single-cell RNA sequencing, immunohistochemistry, proteomics, and multi-level survival analyses. We further examined correlations between <i>RPP40</i> expression and diverse clinical indicators, including tumor stage, treatment response, immune subtype, and demographic characteristics.</p> Results <p><i>RPP40</i> expression was significantly upregulated in most cancers and their subtypes, and it was identified as a broadly essential gene for cancer cell survival. High <i>RPP40</i> expression was significantly associated with advanced tumor stage and poor prognosis, serving as an independent risk factor for overall survival and progression-free survival across multiple independent cohorts. Our multidimensional analytical framework further revealed significant associations between <i>RPP40</i> expression and various features, including pathological stage, major tumor subtypes, and smoking history. Functionally, <i>RPP40</i> likely promotes tumor proliferation by activating cell cycle pathways, and its expression displays strong cell cycle dependency.</p> Conclusion <p>This study systematically elucidates the oncogenic role of <i>RPP40</i> across cancers, establishing it as a novel and translationally promising pan-cancer prognostic biomarker and a potential therapeutic target. The “multi-level clinical–molecular integrative analysis” framework developed herein provides foundational evidence and data support for subsequent precision therapeutic strategies targeting <i>RPP40</i>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comprehensive profiling of RPP40 across human cancers reveals its essential role and multidimensional clinical correlates

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月3日

查看全文
  • Yu-Nan Man,
  • Mao-Lin He

摘要

Background

Ribonuclease P/MRP subunit p40 (RPP40) is a core component of the RNase P/MRP ribonucleoprotein complex, playing a central role in RNA processing. However, its systematic characteristics, clinical significance, and functional mechanisms at the pan-cancer level remain unclear.

Methods

We systematically characterized the pan-cancer expression profile and prognostic value of RPP40 using multi-omics approaches, including pan-cancer expression profiling, CRISPR screening, single-cell RNA sequencing, immunohistochemistry, proteomics, and multi-level survival analyses. We further examined correlations between RPP40 expression and diverse clinical indicators, including tumor stage, treatment response, immune subtype, and demographic characteristics.

Results

RPP40 expression was significantly upregulated in most cancers and their subtypes, and it was identified as a broadly essential gene for cancer cell survival. High RPP40 expression was significantly associated with advanced tumor stage and poor prognosis, serving as an independent risk factor for overall survival and progression-free survival across multiple independent cohorts. Our multidimensional analytical framework further revealed significant associations between RPP40 expression and various features, including pathological stage, major tumor subtypes, and smoking history. Functionally, RPP40 likely promotes tumor proliferation by activating cell cycle pathways, and its expression displays strong cell cycle dependency.

Conclusion

This study systematically elucidates the oncogenic role of RPP40 across cancers, establishing it as a novel and translationally promising pan-cancer prognostic biomarker and a potential therapeutic target. The “multi-level clinical–molecular integrative analysis” framework developed herein provides foundational evidence and data support for subsequent precision therapeutic strategies targeting RPP40.